Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: Evidence and controversies

被引:31
|
作者
Johri, A. M. [1 ]
Heyland, D. K. [2 ,3 ]
Hetu, M. -F. [1 ]
Crawford, B. [1 ]
Spence, J. D. [4 ,5 ]
机构
[1] Queens Univ, Dept Med, Div Cardiol, Cardiovasc Imaging Network, Kingston, ON K7L 2V7, Canada
[2] Queens Univ, Dept Med, Div Community Hlth & Epidemiol, Kingston, ON K7L 2V7, Canada
[3] Queens Univ, Clin Evaluat Res Unit, Kingston, ON K7L 2V7, Canada
[4] Robarts Res Inst, London, ON N6A 5C1, Canada
[5] Univ Western Ontario, London, ON, Canada
关键词
Metabolic syndrome; Diabetes; Atherosclerosis; Cardiovascular disease; Coronary artery disease; Plaque; L-Carnitine; PROPIONYL-L-CARNITINE; LOW-DENSITY-LIPOPROTEIN; ACETYL-L-CARNITINE; PLASMA ADIPONECTIN LEVELS; FATTY-ACID OXIDATION; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; ATHEROSCLEROTIC LESIONS; MICROBIOTA METABOLISM; GLUCOSE-OXIDATION;
D O I
10.1016/j.numecd.2014.03.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
As the incidence of metabolic syndrome increases, there is also a growing interest in finding safe and inexpensive treatments to help lower associated risk factors. L-carntine, a natural dietary supplement with the potential to ameliorate atherosclerosis, has been the subject of recent investigation and controversy. A majority of studies have shown benefit of L-C supplementation in the metabolic syndrome or cardiovascular risk factors. However, recent work has suggested that dietary L-C may accelerate atherosclerosis via gut microbiota metabolites, complicating the role of L-C supplementation in health. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:808 / 814
页数:7
相关论文
共 50 条
  • [31] Metabolic syndrome: genetic insights into disease pathogenesis
    Ziki, Maen D. Abou
    Mani, Arya
    CURRENT OPINION IN LIPIDOLOGY, 2016, 27 (02) : 162 - 171
  • [32] Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome
    Hackett, Geoffrey
    SEXUAL MEDICINE REVIEWS, 2019, 7 (03) : 476 - 490
  • [33] Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients
    Pedersen, Lise
    Nybo, Mads
    Poulsen, Mikael Kjaer
    Henriksen, Jan Erik
    Dahl, Jordi
    Rasmussen, Lars Melholt
    BMC CARDIOVASCULAR DISORDERS, 2014, 14
  • [34] Chemokine Receptor 5, a Double-Edged Sword in Metabolic Syndrome and Cardiovascular Disease
    Zhang, Zhongwen
    Wang, Qiannan
    Yao, Jinming
    Zhou, Xiaojun
    Zhao, Junyu
    Zhang, Xiaoqian
    Dong, Jianjun
    Liao, Lin
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [35] A changing paradigm for prevention of cardiovascular disease: emergence of the metabolic syndrome as a multiplex risk factor
    Grundy, Scott M.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2008, 10 (0B) : B16 - B23
  • [36] Different definitions of the metabolic syndrome and risk for recurrent cardiovascular disease
    Brown, W. Virgil
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2006, 2 (09): : 492 - 493
  • [37] HIV therapy, metabolic syndrome, and cardiovascular risk
    Vivian Pao
    Grace A. Lee
    Carl Grunfeld
    Current Atherosclerosis Reports, 2008, 10 : 61 - 70
  • [38] Lifestyle and Health Behaviors Associated with Metabolic Syndrome and Cardiovascular Disease
    Chung, Goeun
    Kim, Hye-Jin
    METABOLIC SYNDROME AND RELATED DISORDERS, 2024, 22 (02) : 105 - 113
  • [39] Monitoring of Metabolic Syndrome and Cardiovascular Disease in Childhood Cancer Survivors
    Temtanakitpaisan, Yutthapong
    Saengnipanthkul, Suchaorn
    JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 2022, 11 (01) : 17 - 26
  • [40] The link between abdominal obesity, metabolic syndrome and cardiovascular disease
    Ritchie, S. A.
    Connell, J. M. C.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2007, 17 (04) : 319 - 326